China-based TenNor Therapeutics, a developer of dual-acting antibiotics, has raised $25 million in Series B financing. Northern Light Venture Capital led the round with participation from Frontline BioVentures, WuXi PharmaTech Healthcare Fund I, Oriza Venture Capital and Relativity Healthcare Fund.

Source: Press Release